<DOC>
	<DOCNO>NCT01195649</DOCNO>
	<brief_summary>The primary objective prospective , observational , post-marketing study evaluate patient characteristic , pre-treatment treatment duration Renal Cell Carcinoma ( RCC ) patient candidate systematic therapy decision treat Nexavar速 make real-life practice setting approve reimbursement restriction Taiwan . Therefore , main objective study collect data : Prescription pattern : determine factor affect compliance duration treatment special attention give education status , demography , disease detail , pre-treatment , concomitant medication baseline data Nexavar速 treatment efficacy data Adverse event use Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0</brief_summary>
	<brief_title>Advanced Renal Cell Carcinoma , With Failure Unsuitable Prior Interferon-alpha Interleukin-2 Based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients diagnosis advance Renal Cell Carcinoma ( RCC ) decision take investigator prescribe Nexavar速 Taiwan reimbursement guideline Patients must life expectancy least 8 week Exclusion criterion must follow approve local product information . Patients lose followup followup visit final assessment Nexavar速 document .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>